Fuzhou Cornerstone Medical Technology Co., Ltd.

The main purpose of the study is to use the trazodone hydrochloride sustained-release tablets owned by Fuzhou Keystone Pharmaceutical Technology Co., Ltd. as the test preparation and the trazodone hydrochloride sustained-release tablets (trade name: TRITTICO®, specification: 150 mg) licensed by AZ. CHIM.RIUN. ANGELINI FRANCESCO ACRAF S.P.A. as the reference preparation, and to evaluate the bioequivalence of the two preparations under fasting and postprandial conditions through a single-center, randomized, open, single-dose, two-preparation, two-sequence, two-period, double-crossover clinical study. Secondary purpose of the study: to observe the safety of the test preparation and the reference preparation in healthy study participants.